Pharmacological Management of Spasticity in Children With Cerebral Palsy

2013 Albavera-Hernández, 2009, Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: A systematic review of randomized clinical trials, Clinical Rehabilitation, 23, 394, 10.1177/0269215508099860 Albright, 1996, Baclofen in the treatment of cerebral palsy, Journal of Child Neurology, 11, 77, 10.1177/088307389601100202 2019 Arens, 1993, Acid pump blockers: What are their current therapeutic roles, Bailliere's Clinical Gastroenterology, 7, 95, 10.1016/0950-3528(93)90033-O Bax, 2005, Proposed definition and classification of cerebral palsy, April 2005, Developmental Medicine and Child Neurology, 47, 571, 10.1017/S001216220500112X Blackmer, 2016, Management of sleep disorders in children with neurodevelopmental disorders: A review, Pharmacotherapy, 36, 84, 10.1002/phar.1686 Boehringer Ingelheim Pharmaceuticals, Inc. 2009. Clonidine: Highlights of prescribing information, Ridgefield, CT. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017407s034lbl.pdf Buizer, 2019, Effect of continuous intrathecal baclofen therapy in children: A systematic review, Developmental Medicine and Child Neurology, 61, 128, 10.1111/dmcn.14005 Centers for Disease Control and Prevention. (2019). Data and statistics for cerebral palsy. Retrieved from https://www.cdc.gov/ncbddd/cp/data.html Cerebral Palsy Alliance. (2018). Modified Tardieu scale. Retrieved from https://research.cerebralpalsy.org.au/about-cerebral-palsy/assessments-and-outcome-measures/modified-tardieu-scale/#1494200958472-1e8cac2d-70c3 Chung, 2011, Pharmacotherapy of spasticity in children with cerebral palsy, Journal of the Formosan Medical Association = Taiwan Yi Zhi, 110, 215, 10.1016/S0929-6646(11)60033-8 Copeland, 2014, Botulinum toxin A for nonambulatory children with cerebral palsy: A double blind randomized controlled trial, Journal of Pediatrics, 165, 140, 10.1016/j.jpeds.2014.01.050 Dai, 2016, Comparison of efficacy and side effects of oral baclofen versus tizanidine therapy with adjuvant botulinum toxin type A in children with cerebral palsy and spastic equinus foot deformity, Journal of Child Neurology, 31, 184, 10.1177/0883073815587030 Dai, 2008, Botulinum toxin type A with oral baclofen versus oral tizanidine: A nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity, Journal of Child Neurology, 23, 1464, 10.1177/0883073808319074 Delgado, 2017, Safety and efficacy of repeat open-label AbobotulinumtoxinA treatment in pediatric cerebral palsy, Journal of Child Neurology, 32, 1058, 10.1177/0883073817729918 Delgado, 2010, Neurology, 74, 336, 10.1212/WNL.0b013e3181cbcd2f Delgado, 2016, AbobotulinumtoxinA for equinus foot deformity in cerebral palsy: A randomized controlled trial, Pediatrics, 137, 10.1542/peds.2015-2830 Denhoff, 1975, Treatment of spastic cerebral-palsied children with sodium dantrolene, Developmental Medicine and Child Neurology, 17, 736, 10.1111/j.1469-8749.1975.tb04697.x Deon, 2010, Assessment and treatment of movement disorders in children with cerebral palsy, Orthopedic Clinics of North America, 41, 507, 10.1016/j.ocl.2010.06.001 Dhaliwal, 2019 Eek, 2018, Intrathecal baclofen in dyskinetic cerebral palsy: Effects on function and activity, Developmental Medicine and Child Neurology, 60, 94, 10.1111/dmcn.13625 Engle, 1966, The effect of diazepam (Valium) in children with cerebral palsy: A double-blind study, Developmental Medicine and Child Neurology, 8, 661, 10.1111/j.1469-8749.1966.tb01824.x Gillette Children's Specialty Healthcare. Botulinum toxin and phenol (injected spasticity medications). Retrieved from https://www.gillettechildrens.org/conditions-care/botulinum-toxin-and-phenol-injections. Accessed, June 1, 2020 Goyal, 2016, Prospective randomized study of oral diazepam and baclofen on spasticity in cerebral palsy, Journal of Clinical and Diagnostic Research, 10, RC01 Greenblatt, 1989, A large-sample study of diazepam pharmacokinetics, Therapeutic Drug Monitoring, 11, 652, 10.1097/00007691-198911000-00007 Hansel, 2003, Oral baclofen in cerebral palsy: Possible seizure potentiation, Pediatric Neurology, 29, 203, 10.1016/S0887-8994(03)00208-X Haslam, 1974, Dantrolene sodium in children with spasticity, Archives of Physical Medicine and Rehabilitation, 55, 384 He, 2014, Population pharmacokinetics of oral baclofen in pediatric patients with cerebral palsy, Journal of Pediatrics, 164, 1181, 10.1016/j.jpeds.2014.01.029 Heinen, 2010, The updated European Consensus 2009 on the use of botulinum toxin for children with cerebral palsy, European Journal of Paediatric Neurology, 14, 45, 10.1016/j.ejpn.2009.09.005 Holt, 1964, The use of diazepam in childhood cerebral palsy. Report of a small study including electromyographic observations, Annals of Physical Medicine, 16 Hoving, 2007, Intrathecal baclofen in children with spastic cerebral palsy: A double-blind, randomized, placebo-controlled, dose-finding study, Developmental Medicine and Child Neurology, 49, 654, 10.1111/j.1469-8749.2007.00654.x Hwang, 2011, Measuring care and comfort in children with cerebral palsy: The care and comfort caregiver questionnaire, PM and R, 3, 912, 10.1016/j.pmrj.2011.05.017 JHP Pharmaceuticals, LLC. (2011) Dantrium (dantrolene sodium): Highlights from prescribing information. Rochester, MI. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/017443s043s046s048s049lbl.pdf Joynt, 1980, Dantrolene sodium suspension in treatment of spastic cerebral palsy, Developmental Medicine and Child Neurology, 22, 755, 10.1111/j.1469-8749.1980.tb03742.x Kolaski, 2008, Safety profile of multilevel chemical denervation procedures using phenol or botulinum toxin or both in a pediatric population, American Journal of Physical Medicine and Rehabilitation, 87, 556, 10.1097/PHM.0b013e31817c115b 2020 2020 2020 2020 2020 Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. (2020f). Onabotulinumtoxin A. Hudson, OH: Wolters Kluwer Clinical Drug Information, Inc. Lubsch, 2006, Oral baclofen and clonidine for treatment of spasticity in children, Journal of Child Neurology, 21, 1090, 10.1177/7010.2006.00134 Mathew, 2005, Bedtime diazepam enhances well-being in children with spastic cerebral palsy, Pediatric Rehabilitation, 8, 63, 10.1080/13638490410001731180 Matsuda, 2018, Effect of botulinum toxin type A treatment in children with cerebral palsy: Sequential physical changes for 3 months after the injection, Brain and Development, 40, 452, 10.1016/j.braindev.2018.02.003 Micromedex (electronic version) (2020a). Abobotulinumtoxin A. IBM Watson Health, Greenwood Village, Colorado, USA. Retrieved from https://www-micromedexsolutions-com.proxy.hsl.ucdenver.edu/ Micromedex (electronic version) (2020b). Baclofen. IBM Watson Health, Greenwood Village, Colorado, USA. Retrieved fromhttps://www-micromedexsolutions-com.proxy.hsl.ucdenver.edu Milla, 1977, A controlled trial of baclofen in children with cerebral palsy, Journal of International Medical Research, 5, 398 Monbaliu, 2010, Rating scales for dystonia in cerebral palsy: Reliability and validity, Developmental Medicine and Child Neurology, 52, 570, 10.1111/j.1469-8749.2009.03581.x Murphy, 2002, Intrathecal baclofen therapy in children with cerebral palsy: Efficacy and complications, Archives of Physical Medicine and Rehabilitation, 83, 1721, 10.1053/apmr.2002.36068 Mutlu, 2008, Reliability of Ashworth and Modified Ashworth scales in children with spastic cerebral palsy, BMC Musculoskeletal Disorders, 9, 44, 10.1186/1471-2474-9-44 Navarrete-Opazo, 2016, Effectiveness of oral baclofen in the treatment of spasticity in children and adolescents with cerebral palsy, Archives of Physical Medicine and Rehabilitation, 97, 604, 10.1016/j.apmr.2015.08.417 Nogen, 1979, Effect of dantrolene sodium on the incidence of seizures in children with spasticity, Child's Brain, 5, 420 2016 2013 On, 1999, Mechanisms of action of phenol block and botulinus toxin Type A in relieving spasticity: Electrophysiologic investigation and follow-up, American Journal of Physical Medicine and Rehabilitation, 78, 344, 10.1097/00002060-199907000-00010 Paget, 2018, Systemic adverse events after botulinum neurotoxin A injections in children with cerebral palsy, Developmental Medicine and Child Neurology, 60, 1172, 10.1111/dmcn.13995 2008 Russell, 2002, 326 Sabus, 2019, Management of self-injurious behaviors in children with neurodevelopmental disorders: A pharmacotherapy overview, Pharmacotherapy, 39, 645, 10.1002/phar.2238 Scheinberg, 2006, Oral baclofen in children with cerebral palsy: A double-blind cross-over pilot study, Journal of Paediatrics and Child Health, 42, 715, 10.1111/j.1440-1754.2006.00957.x Schneider, 2001, Health-related quality of life and functional outcome measures for children with cerebral palsy, Developmental Medicine and Child Neurology, 43, 601, 10.1017/S0012162201001098 Snyder, 1967, 1-[(5-arylfurfurylidene)amino]hydantoins. A new class of muscle relaxants, Journal of Medicinal Chemistry, 10, 807, 10.1021/jm00317a011 Tickner, 2012, An overview of drug therapies used in the treatment of dystonia and spasticity in children, Archives of Disease in Childhood. Education and Practice Edition, 97, 230, 10.1136/archdischild-2011-301170 Wong, 2004, Clinical effects of botulinum toxin A and phenol block on gait in children with cerebral palsy, American Journal of Physical Medicine and Rehabilitation, 83, 284, 10.1097/01.PHM.0000118038.02326.CA Worthington, 2013, Cerebral palsy, 367